Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

3 Cash-Producing Stocks with Questionable Fundamentals

December 28, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.7% in the afternoon session after investor anxiety mounted ahead of a key U.S. Food and Drug Administration (FDA) decision for its...

Why Corcept (CORT) Stock Is Trading Lower Today

December 23, 2025

Corcept has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.8% to $81.75 per share while the index has gained 13.9%.

Topics Artificial Intelligence

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings?

December 16, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.2% in the afternoon session after investment bank UBS initiated coverage of the company with a Neutral rating.

Topics Stocks

Why Corcept (CORT) Stock Is Down Today

December 16, 2025

Corcept (CORT) Q3 2025 Earnings Call Transcript

Topics Artificial Intelligence Economy Supply Chain

Corcept (CORT) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Topics Earnings Intellectual Property

Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Strong Growth and Technical Breakout Case ↗

November 22, 2025

Corcept Therapeutics (CORT) combines strong fundamentals, including robust revenue growth and a healthy balance sheet, with a positive technical breakout setup.

Via Chartmill

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Discover Corcept Therapeutics (CORT), a debt-free pharma stock with strong growth forecasts, solid profitability, and a reasonable valuation for balanced investing.

Topics Economy

CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Case Study in Affordable Growth Investing ↗

November 18, 2025

Via Chartmill

1 Growth Stock with Explosive Upside and 2 We Brush Off

November 17, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Looking back on branded pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Corcept (NASDAQ:CORT) and its peers.

Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT)

November 12, 2025

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

Topics Artificial Intelligence Intellectual Property

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Corcept Therapeutics’ third quarter results drew a negative market reaction as the company’s revenue missed Wall Street expectations, despite robust year-on-year growth. Management highlighted...

Topics Artificial Intelligence Stocks

The 5 Most Interesting Analyst Questions From Corcept’s Q3 Earnings Call

November 11, 2025

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

Topics Earnings

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Peering Into Corcept Therapeutics Inc's Recent Short Interest ↗

November 06, 2025

Via Benzinga

CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook

November 05, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue...

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings

November 04, 2025

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

November 04, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting results this Tuesday after market close. Here’s what to look for.

Corcept Earnings: What To Look For From CORT

November 02, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This...

Topics Artificial Intelligence

3 Healthcare Stocks We Steer Clear Of

October 31, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Topics Stocks

3 Cash-Producing Stocks with Open Questions

October 29, 2025

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 28, 2025

Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk ↗

Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock ↗

October 20, 2025

Via Benzinga

October 20, 2025

Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor...

Via Stocktwits

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

October 19, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm

October 16, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 7.7% in the afternoon session after it submitted a Marketing Authorization Application to the European Medicines Agency for its...

Corcept (CORT) Shares Skyrocket, What You Need To Know

October 15, 2025

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

October 14, 2025